GPNMB (Glycoprotein NMB, also known as Osteoactivin or Hematopoietic Growth Factor Inducible Neurokinin-1) is a transmembrane glycoprotein that has emerged as an important biomarker in neurodegenerative diseases. Originally identified in metastatic melanoma cells, GPNMB is expressed in various tissues including brain, where it plays roles in immune regulation, cell adhesion, and tissue remodeling. Elevated GPNMB levels have been detected in the cerebrospinal fluid and blood of patients with Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, making it a potential biomarker for disease diagnosis and progression[@nakajima2000].
Overview
GPNMB is a type I transmembrane protein belonging to the osteoblast lineage family. It possesses an extracellular domain containing a polycystic kidney disease-like domain, a transmembrane region, and a short cytoplasmic tail. The protein is shed from the cell surface through proteolytic cleavage, releasing a soluble form that can be detected in biological fluids[@rose2009].
Key Characteristics
Gene: GPNMB located on chromosome 7p15.3
Protein size: ~560 amino acids (full-length), ~95 kDa
Expression: Low in most healthy tissues, upregulated in disease states
Soluble form: Generated via ADAM10/ADAM17-mediated shedding
Receptor: Integrin αvβ3 has been proposed as a binding partner
Structure and Function
Protein Domains
...
GPNMB (Glycoprotein NMB)
Introduction
GPNMB (Glycoprotein NMB, also known as Osteoactivin or Hematopoietic Growth Factor Inducible Neurokinin-1) is a transmembrane glycoprotein that has emerged as an important biomarker in neurodegenerative diseases. Originally identified in metastatic melanoma cells, GPNMB is expressed in various tissues including brain, where it plays roles in immune regulation, cell adhesion, and tissue remodeling. Elevated GPNMB levels have been detected in the cerebrospinal fluid and blood of patients with Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, making it a potential biomarker for disease diagnosis and progression[@nakajima2000].
Overview
GPNMB is a type I transmembrane protein belonging to the osteoblast lineage family. It possesses an extracellular domain containing a polycystic kidney disease-like domain, a transmembrane region, and a short cytoplasmic tail. The protein is shed from the cell surface through proteolytic cleavage, releasing a soluble form that can be detected in biological fluids[@rose2009].
Key Characteristics
Gene: GPNMB located on chromosome 7p15.3
Protein size: ~560 amino acids (full-length), ~95 kDa
Expression: Low in most healthy tissues, upregulated in disease states
Soluble form: Generated via ADAM10/ADAM17-mediated shedding
Receptor: Integrin αvβ3 has been proposed as a binding partner
Structure and Function
Protein Domains
N-terminal signal peptide: Targets protein for secretion
Propeptide: Cleaved in the Golgi apparatus
Extracellular domain: Contains the majority of functional motifs
Polycystic kidney disease (PKD) domain
RGD motif (integrin-binding)
N-linked glycosylation sites
4. Transmembrane domain: Single pass helix
Cytoplasmic tail: Contains signaling motifs
Biological Functions
Normal Physiology
Cell adhesion and migration: Via integrin interactions
Tissue repair: Expressed in healing wounds and bone remodeling
Immune regulation: Modulates macrophage and microglial activity
Iron metabolism: Associates with ferroportin
Role in Neurodegeneration
GPNMB is upregulated in the central nervous system in response to:
Amyloid-beta exposure: Increased expression in AD brain
The study of Gpnmb (Glycoprotein Nmb) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Nakajima C, Tsuji Y, Morino N, et al, GPNMB, a tissue-specific membrane protein, as an osteogenic factor (2000)](https://pubmed.ncbi.nlm.nih.gov/10831876/)
[Rose AA, Siegel PM, Osteoactivin: an ancient cytokine and growth factor that mediates EMT, metastasis and tumor progression (2009)](https://pubmed.ncbi.nlm.nih.gov/19718048/)
[Huang L, Jia J, Liu R, et al, Decreased serum GPNMB is associated with the severity of Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/31954788/)
[Zhang Y, Chen K, Sloan SA, et al, An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex (2014)](https://pubmed.ncbi.nlm.nih.gov/25186741/)
[Perner C, Perner F, Gaur A, et al, GPNMB is increased in the substantia nigra of patients with Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32790103/)
[Zhou L, Luo J, Wang J, et al, GPNMB: a promising therapeutic target for neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36148723/)
[Hüttenrauch M, Ogrodnik M, Wacker R, et al, Glycoprotein NMB: a novel biomarker for Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25649654/)
[Satoh J, Kino Y, Yanaizu M, et al, GPNMB is expressed in human neurons but not in astrocytes (2015)](https://pubmed.ncbi.nlm.nih.gov/25553990/)
[Konishi H, Kiyama H, Microglial TREM2/DAP12 signaling: a promising therapeutic target for neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35784067/)
[Umeda T, Kanda M, Takami K, et al, GPNMB as a biomarker in cerebrospinal fluid for Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33662156/)